Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Faxeladol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 9/20 | 0.50 |
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 0.50 |
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Faxeladol SCHEMBL149508 | 1.00 | SLC6A4 (0.50) | SLC6A4SLC6A2OPRM1MEN1OPRD1 | |
| Faxeladol SCHEMBL5686250 | 1.00 | SLC6A4 (0.50) | SLC6A4SLC6A2OPRM1MEN1OPRD1 | |
| Faxeladol SCHEMBL354208 | 1.00 | SLC6A4 (0.50) | SLC6A4SLC6A2OPRM1MEN1OPRD1 | |
| Faxeladol SCHEMBL30616185 | 1.00 | SLC6A4 (0.50) | SLC6A4SLC6A2OPRM1MEN1OPRD1 | |
| Faxeladol SCHEMBL616828 | 1.00 | SLC6A4 (0.50) | SLC6A4SLC6A2OPRM1MEN1OPRD1 | |
| Faxeladol SCHEMBL12027609 | 1.00 | SLC6A4 (0.50) | SLC6A4SLC6A2OPRM1MEN1OPRD1 | |
| Faxeladol SCHEMBL28793358 | 1.00 | SLC6A4 (0.50) | SLC6A4SLC6A2OPRM1MEN1OPRD1 | |
| Faxeladol SCHEMBL7893759 | 0.99 | SLC6A4 (0.49) | SLC6A4SLC6A2OPRM1MEN1OPRD1 | |
| Faxeladol SCHEMBL619079 | 0.99 | SLC6A4 (0.49) | SLC6A4SLC6A2OPRM1MEN1OPRD1 | |
| Faxeladol SCHEMBL465057 | 0.99 | SLC6A4 (0.49) | SLC6A4SLC6A2OPRM1MEN1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 509 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765303-B2 | ORAL TABLET SAFEGUARDED AGAINST ABUSE | GRUENENTHAL GMBH (DE) | 2022-11-23 | — | — | EP | claimed |
| US-10160719-B2 | Pharmaceutical salts | GRUNENTHAL GMBH (DE) | 2018-12-25 | — | — | US | claimed |
| US-20170137370-A1 | PHARMACEUTICAL SALTS | Grünenthal GmbH (DE) | 2017-05-18 | — | — | US | claimed |
| US-20160279150-A1 | Combination of Selected Analgesics and Cox-II Inhibitors | GRUENENTHAL GMBH (DE) | 2016-09-29 | — | — | US | claimed |
| US-20130296414-A1 | 1-Phenyl-2-Dimethylaminomethyl Cyclohexane Compounds And Therapies For Depressive Symptoms, Pain and Incontinence | GRUENENTHAL GMBH (DE) | 2013-11-07 | — | — | US | claimed |
| US-20130245125-A1 | HCl Polymorphs of 3-((2-(Dimethylamino)methyl(cyclohex-1-yl))phenol | GRUENENTHAL GMBH (DE) | 2013-09-19 | — | — | US | claimed |
| US-20130109733-A1 | Combination of Selected Analgesics and Cox-II Inhibitors | GRUENENTHAL GMBH (DE) | 2013-05-02 | — | — | US | claimed |
| US-8420691-B2 | Combination of selected analgesics and COX-II inhibitors | GRUENENTHAL GMBH (DE) | 2013-04-16 | — | — | US | claimed |
| US-8404749-B2 | Method of inhibiting inflammatory pain | GRUENENTHAL GMBH (DE) | 2013-03-26 | — | — | US | claimed |
| EP-1928441-B1 | RETARDFORMULATION COMPRISING 3-(2-DIMETHYLAMINOMETHYLCYCLOHEXYL)PHENOL | GRUENENTHAL GMBH (DE) | 2013-02-27 | — | — | EP | claimed |
| US-20040043968-A1 | Use of 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treatment of urinary incontinence | GRUENENTHAL GMBH (DE) | 2004-03-04 | — | — | US | claimed |
| EP-1390023-A2 | PHARMACEUTICAL SALTS | Grünenthal GmbH (DE) | 2004-02-25 | — | — | EP | claimed |
| WO-2004009067-A1 | 1-PHENYL-2-DIMETHYLAMINOMETHYL CYCLOHEXANE COMPOUNDS USED FOR THE THERAPY OF DEPRESSIVE SYMPTOMS, PAIN, AND INCONTINENCE | Grünenthal GmbH (DE) | 2004-01-29 | — | — | WO | claimed |
| WO-2003099268-A1 | COMBINATION OF SELECTED OPIOIDS WITH OTHER ACTIVE SUBSTANCES FOR USE IN THE THERAPY OF URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2003-12-04 | — | — | WO | claimed |
| EP-1337246-A2 | USE OF 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXANE COMPOUNDS FOR TREATING URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2003-08-27 | — | — | EP | claimed |
| WO-2003024444-A1 | COMBINATION OF SELECTED OPIOIDS WITH MUSCARINE ANTAGONISTS FOR TREATING URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2003-03-27 | — | — | WO | claimed |
| WO-2002067651-A2 | PHARMACEUTICAL SALTS | Grünenthal GmbH (DE) | 2002-09-06 | — | — | WO | claimed |
| WO-2002067916-A2 | PHARMACEUTICAL SALTS | Grünenthal GmbH (DE) | 2002-09-06 | — | — | WO | claimed |
| WO-2002043712-A2 | USE OF 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXANE COMPOUNDS FOR TREATING URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2002-06-06 | — | — | WO | claimed |
| US-RE37355-E1 | 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients | GRUENENTHAL GMBH (DE) | 2001-09-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160719-B2 | Pharmaceutical salts | SLC5A1, SLC5A2, SLC35A1 | SLC6A4 83/4885SLC6A2 164/4885OPRM1 2283/4885 |
| US-20130245125-A1 | HCl Polymorphs of 3-((2-(Dimethylamino)methyl(cyclohex-1-yl))phenol | HCLS1, PEAK1, PAH | SLC6A4 878/4885SLC6A2 659/4885OPRM1 16/4885 |
| US-20170137370-A1 | PHARMACEUTICAL SALTS | SLC5A1, SLC5A2, SLC35A1 | SLC6A4 83/4885SLC6A2 164/4885OPRM1 2283/4885 |
| US-20130296414-A1 | 1-Phenyl-2-Dimethylaminomethyl Cyclohexane Compounds And Therapies For Depressive Symptoms, Pain and Incontinence | PNMT, HNMT, OPRM1 | SLC6A4 109/4885SLC6A2 136/4885OPRM1 3/4885 |
| US-20130109733-A1 | Combination of Selected Analgesics and Cox-II Inhibitors | OPRK1, PTGER2, OPRL1 | SLC6A4 2071/4885SLC6A2 1114/4885OPRM1 4/4885 |
| US-20160279150-A1 | Combination of Selected Analgesics and Cox-II Inhibitors | OPRK1, PTGER2, OPRL1 | SLC6A4 2071/4885SLC6A2 1114/4885OPRM1 4/4885 |
| US-20040043968-A1 | Use of 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treatment of urinary incontinence | UROD, DDC, ODC1 | SLC6A4 4036/4885SLC6A2 2371/4885OPRM1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.